Advertisement

 

 

Predominance of Hepatitis B Virus genotype A among treated HIV infected patients experiencing high HBV drug resistance in Nairobi, Kenya.

Predominance of Hepatitis B Virus genotype A among treated HIV infected patients experiencing high HBV drug resistance in Nairobi, Kenya.
Author Information (click to view)

Mabeya SN, Ngugi CW, Lihana RW, Khamadi SA, Nyamache AK,


Mabeya SN, Ngugi CW, Lihana RW, Khamadi SA, Nyamache AK, (click to view)

Mabeya SN, Ngugi CW, Lihana RW, Khamadi SA, Nyamache AK,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

AIDS research and human retroviruses 2017 03 19() doi 10.1089/AID.2017.0019

Abstract

HBV/HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive. To evaluate the HBV genetic diversity and drug resistance associated mutations among drug experienced HIV patients, the genetic analysis of the partial HBV-pol-reverse trancriptase gene was successfully sequenced from 13 samples. Analysis of the sequences showed that all (13) the sequences belonged to genotype A. Nucleos(t)ide drug resistance mutations were found in six (6) patients. Five subjects had rtV173L, rtL180M, rtM204V and one with rtL180M, rtM204V major mutations. HBV genotype A remains the most predominant genotype circulating in Nairobi city with detected high level of HBV drug resistance to Lamivudine telbivudine and emtricitabine. The detected circulating HBV genotype A in Nairobi reflects its possible spread in the population with its origin being within the country. We suggest that patients should not be on lamivudine monotherapy. These individuals should be managed on combination of tenofovir plus lamivudine or emtricitabine therapy in order to prevent the emergence of HBV drug resistant variants alongside a continuous surveillance monitoring of drug resistance and HBV genotypes.

Submit a Comment

Your email address will not be published. Required fields are marked *

three × 5 =

[ HIDE/SHOW ]